biostudies-literatureUnknown28(13)Konopleva M<h4>Purpose</h4>To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia.<h4>Patients and methods</h4>Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax + azacitidine. Enrolled patients were ineligible for intensive therapy due to age ≥75 years and/or comorbidities. Patients on venetoclax + azacitidine received venetoclax 400 mg orally (days 1-28) and azacitidine (75 mg/m2; days 1-7/28-day cycle). FLT3 mutation was analyzed centrally on pretreatment bone marrow aspirates.<h4>Results</h4>In the biomarker evaluable population, Clinical cancer research : an official journal of the American Association for Cancer Research2744-2752https://www.ebi.ac.uk/biostudies/studies/S-EPMC9365380biostudies-literatureImpact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia.PMC9365380Miller CLPratz KWPullarkat VRecher CThirman MJGarcia JSKantarjian HMKonopleva MDiNardo CDPotluri JWei AHDail MChyla BDuan YfalseImpact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia.<h4>Purpose</h4>To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia.<h4>Patients and methods</h4>Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax + azacitidine. Enrolled patients were ineligible for intensive therapy due to age ≥75 years and/or comorbidities. Patients on venetoclax + azacitidine received venetoclax 400 mg orally (days 1-28) and azacitidine (75 mg/m2; days 1-7/28-day cycle). FLT3 mutation was analyzed centrally on pretreatment bone marrow aspirates.<h4>Results</h4>In the biomarker evaluable population, 2022-01-01T00:00:00Z2022 Jul2026-05-09T22:15:57.874Z2025-04-04T20:22:15.153ZS-EPMC93653803506396510.1158/1078-0432.CCR-21-3405